Introduction {#s1}
============

Allergic asthma is a common childhood illness and can be triggered by exposure to aeroallergens such as house dust mite (HDM). Hallmark features of the disease include aberrant T helper 2 (Th2) type responses, airway hyperreactivity, eosinophilic inflammation, increased IgE and mucus hypersecretion ([@bib12]).

The balance between pro-inflammatory CD4+ Th2 cells and regulatory T cells, including CD4+Foxp3+ regulatory T cells (Treg) and CD4+Foxp3-, interleukin-10 (IL-10)-producing Type one regulatory T cells (Tr1) cells, is a significant determinant in the development of allergic disease ([@bib34]). Allergen-specific immunotherapy may re-establish tolerance in part by expanding these regulatory T cell populations ([@bib1]; [@bib32]). There is therefore great interest in developing stable, antigen specific regulatory T cells for treatment of asthma and allergies ([@bib3]).

The anti-inflammatory cytokine interleukin 10 (IL-10) is critical for immune tolerance to airway allergens ([@bib20]). The suppressive capabilities of Tr1 cells are primarily attributed to IL-10 while Foxp3+ T cells exert regulatory function in several ways, including via IL-10 production, ([@bib30]; [@bib27]; [@bib47]; [@bib26]; [@bib33]). IL-10 can limit both Th2 differentiation and survival ([@bib11]) and endogenous T cell-derived IL-10 limits the development of pathogenic Th2 responses during allergen sensitization ([@bib48]; [@bib45]). Indeed, the development of Tr1-like cells is critical to the success of allergen-specific immunotherapy ([@bib1]; [@bib32]). There is therefore great interest in the factors involved in Tr1 development ([@bib28]; [@bib8]; [@bib13]; [@bib49]) and considerable progress has been made toward engineering Tr1-like cells in vitro for potential therapeutic applications ([@bib18]).

However, much about naturally-arising Tr1 cells and endogenous IL-10 production in allergic airway disease remains unknown ([@bib46]). In particular, the contribution of antigen-specific Tr1 cells to tolerogenic memory is unclear. Given the persistence of allergen-specific immunity ([@bib21]) this information may prove vital for the development of successful Tr1-directed immunotherapies.

Here, we characterize the spatial and temporal dynamics of endogenous IL-10-producing T cells in a mouse model of HDM-induced allergic airway inflammation. For this purpose, we have used a mouse strain carrying a stable IL-10 reporter, the 10BiT mouse ([@bib31]). This strain carries multiple copies of a bacterial artificial chromosome (BAC) transgene containing a CD90.1 construct under the control of the IL-10 promoter such that cells that previously made IL-10 express CD90.1 which persists for some time after cessation of IL-10 production. This strain was previously crossed against the Foxp3-eGFP mouse strain to facilitate discrimination between Foxp3- Tr1 from Foxp3+ Treg ([@bib31]).

Using these animals, we have analyzed the population frequencies and cytokine production profiles of Tr1-like cells in multiple tissues at various stages of allergic airway inflammation including sensitization, challenge, resolution, and memory. To determine the functional contribution of Tr1-like memory T-cell populations we perform loss and gain of function studies by deleting these cells or adoptively transferring them before re-challenge with the allergen. Together, these studies elucidate the cellular source of IL-10 in allergic inflammation, their functional stability, and their contribution to tolerogenic memory in the lung.

Results {#s2}
=======

IL-10-producing T cells accumulate at site of allergen sensitization {#s2-1}
--------------------------------------------------------------------

To interrogate the patterns of endogenous IL-10 production in allergic airway inflammation we used a house dust mite (HDM) induced murine model ([Figure 1A](#fig1){ref-type="fig"}). In this model, animals are sensitized to crude house dust mite (HDM) protein intranasally (i.n.) over 2 weeks while control animals are given phosphate buffered saline (PBS). Analysis of the inflammatory response is carried out 4 days after completion of the challenge series. This model recapitulates key features of allergic responses associated with type two inflammation, with HDM- sensitized animals showing an increase in total number of cells ([Figure 1B](#fig1){ref-type="fig"}) and total number of eosinophils ([Figure 1C](#fig1){ref-type="fig"}) in the broncho-alveolar lavage (BAL) as compared to controls. Also, the lungs of HDM-sensitized animals exhibited an increase in peribronchiolar and perivascular inflammation ([Figure 1D](#fig1){ref-type="fig"}). The levels of total IgE were also elevated in the BAL supernatants obtained from HDM-sensitized animals ([Figure 1E](#fig1){ref-type="fig"}).

![IL-10-producing T cells accumulate at site of allergen sensitization.\
C57Bl/6 mice were administered either PBS as control or crude HDM containing 20μg total protein in 50μl intranasally (i.n.) Six times over 2 weeks as shown. Terminal analysis was performed 4 days after last challenge. (**B**) The total number of cells and (**C**) total number of eosinophils in the BAL were determined. Data are pooled from two experiments. Each symbol represents a single animal. Error bars represent standard error of mean. n=10 for control group, n=10 for HDM group. (**D**) Representative haematoxylin and eosin stained lung sections showing perivascular and peribronchiolar inflammation in PBS control and HDM-sensitized animals. (**E**) The level of IgE in BAL supernatant was determined by ELISA. n=5 for control group, n=5 for HDM group. Error bars represent standard deviation of mean. Statistical significance was determined using an unpaired two tailed students t-test. Representative flow cytometry plots showing different T cell subsets as identified by surface expression of CD90.1 and Foxp3eGFP in the (**F**) BAL, (**G**) lungs, (**H**) pulmonary lymph nodes, and (**I**) spleens of control or HDM-treated mice 4 days after final challenge. The frequency of IL-10-producing Foxp3- (CD90.1+Foxp3-), IL-10-producing Foxp3+ (CD90.1+Foxp3+) and Foxp3+ cells which do not produce IL-10 (CD90.1-Foxp3+) within all CD4+ T cells in the four sites are plotted. Data are pooled from two experiments. Error bars represent standard error of mean. n=10 for control group, n=10 for HDM group. Data are representative of 4 independent experiments. Statistical significance was determined using 2-way ANOVA (post hoc test: Sidaks). \*P$\leq$0.05, \*\*P$\leq$0.01, \*\*\*P$\leq$0.001 \*\*\*\*P$\leq$0.0001. PBS=Phosphate buffered saline, HDM=house dust mite, i.n=intranasally, BAL=bronchoalveolar lavage.\
10.7554/eLife.44821.003Figure 1---source data 1.IL-10-producing T cells accumulate at site of allergen sensitization.](elife-44821-fig1){#fig1}

Next, using the 10BiT/Foxp3eGFP strain (***Tg(Il10-Thy1)1Weav* crossed to *Foxp3^tm2Tch^***) ([@bib31]), we characterized the endogenous IL-10 response in this model. This strain carries dual reporters for IL-10 and Foxp3. A bacterial artificial chromosome (BAC) containing CD90.1 under the control of an IL-10 promoter enables the detection of cells that have produced IL-10 via the expression of cell surface CD90.1 while a GFP knocked into the Foxp3 locus tracks endogenous Foxp3 expression ([@bib31]). Using this model, we found that the frequency of CD90.1+ Foxp3-CD4+ Tr1-like cells was increased in the HDM-sensitized animals in the BAL and the lungs ([Figure 1F,G](#fig1){ref-type="fig"}), the sites of allergen challenge, but not in the pulmonary lymph node ([Figure 1H](#fig1){ref-type="fig"}) or the spleen ([Figure 1I](#fig1){ref-type="fig"}). Thus, CD90.1+Foxp3- Tr1-like cells specifically accumulated at the site of allergen challenge.

Lung Tr1-like cells are located in the lung parenchyma {#s2-2}
------------------------------------------------------

We used intravenous labeling to further discriminate between lung-resident versus circulating cells ([@bib2]). For staining non-tissue-resident circulating cells in the lung, we injected CD45 antibody retro-orbitally 2 min before mice were euthanized. We found that the majority of CD90.1+Foxp3-CD4+ T cells were parenchymal ([Figure 2A--D](#fig2){ref-type="fig"}) as were the CD90.1+Foxp3+CD4+ T cells ([Figure 2E](#fig2){ref-type="fig"}). In contrast more than half of CD90.1-Foxp3+CD4+ T cells and about half of the CD90.1-Foxp3- CD4+ T cells were in the lung vasculature ([Figure 2F--G](#fig2){ref-type="fig"}). These data indicated that both CD90.1+Foxp3- and CD90.1+Foxp3+ T cells are primarily within the lung parenchyma.

![IL-10-producing cells are located in the lung parenchyma at peak of inflammation.\
Intravascular (IV) labeling of cells was performed by retro orbital injection of CD45 antibody and animals were euthanized 2 minutes after injection. Analysis was carried at peak of inflammation day 16-post first house dust mite challenge. (**A**) Efficacy of labeling of cells was assessed in blood and in the lungs. (**B**) The proportion of cells in blood and lung, which were labeled with antibody IV, was quantified. Error bars are standard deviation. Statistical significance was determined using a paired two tailed students t-test. n.d = not detected (**C**) Gating scheme showing the different subsets: CD90.1+ (IL-10+) Foxp3-, CD90.1+ (IL-10+) Foxp3+, CD90.1- (IL-10-) Foxp3+ and CD90.1- (IL-10-) Foxp3- within the CD4 T cells in the lungs. The proportion of circulating CD45+IV labeled cells or tissue-resident (CD45-) within the CD90.1+ (IL-10+) Foxp3-, CD90.1- (IL-10-) Foxp3+ and CD90.1- (IL-10-) Foxp3- is also shown. (**D**) Proportion of cells, which are circulating or resident within the CD90.1+ (IL-10+) Foxp3-, (**E**) within CD90.1- (IL-10-) Foxp3+ and (**F**) within CD90.1- (IL-10-) Foxp3- was quantified. Data are representative of 2 independent experiments\*\*P$\leq$0.01.\
10.7554/eLife.44821.005Figure 2---source data 1.IL-10-producing cells are located in the lung parenchyma at peak of inflammation.](elife-44821-fig2){#fig2}

CD4+Foxp3- T cells are the primary source of IL-10 at the peak of the inflammatory response {#s2-3}
-------------------------------------------------------------------------------------------

Since different cell types can produce IL-10, we further distinguished T cell-derived and non-T cell-derived sources of IL-10 using CD90.1 expression in control and HDM-sensitized animals ([Figure 3A](#fig3){ref-type="fig"}). We found marked differences in the composition of CD90.1+ cells between control and HDM-sensitized animals. In control animals, non-T cells (CD3-) comprised the majority of CD90.1+ whereas in HDM-sensitized animals, the majority of CD90.1+ were Foxp3-CD4+ T cells ([Figure 3B](#fig3){ref-type="fig"}). The total number of CD90.1+ Foxp3- cells was predominantly increased in the lungs in comparison to other CD90.1 + subsets ([Figure 3C](#fig3){ref-type="fig"}). The MFI of CD90.1 as a correlate of IL-10 production was also increased in the CD90.1+Foxp3- subsets as compared to CD3+CD4- and CD3-CD4- subsets ([Figure 3D](#fig3){ref-type="fig"}). Thus, the increase in the frequency of Tr1-like cells at the site of allergen sensitization could be attributed to the accumulation of CD90.1+ Foxp3- CD4+ T cells in the lungs. These changes were specific to the site of allergen challenge as neither the frequency of total CD90.1+ cells nor their composition was changed in the spleens of sensitized animals ([Figure 3---figure supplement 1A--C](#fig3s1){ref-type="fig"}).

![CD4+Foxp3- T cells are the prominent IL-10 competent cells at the peak of inflammatory response.\
(**A**) Gating scheme to identify the composition of IL-10-producing cells in the lungs of control or HDM- treated mice. (**B**) Composition of IL-10-producing cells is shown by plotting the frequency of indicated cell types within all IL-10-producing (CD90.1+) cells in control or HDM-treated lungs. Each column is one animal. n=5 for control group, n=5 for HDM group. (**C**) Total number of indicated subsets in the lungs of HDM-treated animals at peak of inflammation. (**D**) Median fluorescence intensity of CD90.1 in indicated subsets. Statistical significance was determined using one-way ANOVA (post hoc test: Tukey). Data representative of three independent experiments. \*P$\leq$0.05, \*\*P$\leq$0.01, \*\*\*P$\leq$0.001.\
10.7554/eLife.44821.009Figure 3---source data 1.CD4+Foxp3- T cells are the prominent IL-10 competent cells at the peak of inflammatory response.](elife-44821-fig3){#fig3}

Previously described Tr1 markers do not distinguish IL-10-producing Foxp3- T cells from IL-10-producing Foxp3+ Treg in this model {#s2-4}
---------------------------------------------------------------------------------------------------------------------------------

We next investigated whether CD90.1+ Foxp3- cells in the lungs of HDM-sensitized animals expressed phenotypic markers previously associated with Tr1 cells in comparison to the other CD4+ T cells subsets ([@bib13]; [@bib35]; [@bib51]).

We measured the expression of CD25, the alpha subunit of the IL-2 receptor, which is highly expressed on Foxp3+Tregs and correlates with their suppressive function ([@bib38]). CD25 was explicitly increased on Foxp3+ cells irrespective of IL-10 production, though CD90.1+Foxp3+ exhibited a lower level of expression in comparison to CD90.1-Foxp3+ cells ([Figure 4A](#fig4){ref-type="fig"}).

![Phenotype of lung CD4 T cell subsets at the peak of inflammation.\
The median fluorescence intensity of (**A**) CD25, (**B**) KLRG1, (**C**) PD-1, and percentage of (**D**) CD25, (**E**) KLRG1, (**F**) PD-1 and MFI of (**G**) CD44, (**H**) LAG3, (**I**) CD49b and percentage of (**J**) CD44, (**K**) LAG3 and (**L**) CD49b in indicated CD4+ T cell subsets in the lungs of HDM-treated mice 4 days after last challenge. Data are pooled from 2 experiments. Error bars represent standard error of mean. n=9-10 for control group, n=9-10 for HDM group for CD44, LAG3, CD49b and CD25. n=5 for control group, n=5 for HDM group for KLRG-1 and PD-1. Statistical significance was determined using 2-way ANOVA (post hoc test: Bonferroni). Data are representative of three independent experiments. \# represents significant difference from CD90.1-Foxp3- cells and represents significant difference from CD90.1-Foxp3+ cells. \#P$\leq$0.05, \#\# P$\leq$0.01, P$\leq$0.01, \#\#\#\#P$\leq$0.001 P$\leq$0.001.\
10.7554/eLife.44821.013Figure 4---source data 1.Phenotype of lung CD4 T cell subsets at the peak of inflammation.](elife-44821-fig4){#fig4}

We also quantified the expression of KLRG1 and PD1, markers of senescence or exhaustion respectively that correlate with the suppressive function of regulatory T cells ([@bib9]; [@bib42]; [@bib43]). Tr1 cells also express PD-1 during immunotherapy ([@bib9]). We found that both KLRG1 and PD-1 are highly expressed on CD90.1+ cells irrespective of Foxp3 expression ([Figure 4B,C](#fig4){ref-type="fig"}). These differences were reflected in the frequency of cells expressing these markers ([Figure 4D--F](#fig4){ref-type="fig"})

All IL-10-producing CD4+ T cells irrespective of Foxp3 expression express high levels of CD44 ([Figure 4G](#fig4){ref-type="fig"}). CD44 is a receptor for hyaluronan and studies from our group and others have shown that it can potentiate IL-10 responses in CD4+ T cells ([@bib5]; [@bib51]). Despite this association, CD44- /- mice did not show a decrease in the frequency of CD90.1+Foxp3- or CD90.1+Foxp3+ cells in the HDM model, suggesting that CD44 is dispensable for their induction ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

LAG3, an inhibitory immune receptor, and CD49b, an integrin alpha subunit, have been proposed to define Tr1 cells ([@bib13]). We found that while LAG3 expression distinguished CD90.1+Foxp3- from CD90.1-Foxp3- T cells, it did not distinguish between CD90.1+Foxp3- and either CD90.1+Foxp3+ cells or CD90.1-Foxp3+ cells ([Figure 4H](#fig4){ref-type="fig"}). CD49b expression was similar between all the different subsets ([Figure 4I](#fig4){ref-type="fig"}). Similar patterns were also observed for the frequency of cells expressing these markers ([Figure 4J--L](#fig4){ref-type="fig"}).

Together these data indicate that CD90.1+Foxp3- cells in this model are typically CD44^hi^, CD25^lo^, PD-1^hi^, LAG3^hi^, and KLRG^int^. Thus, these cells share most markers previously associated with Tr1 cells (i.e. they are 'Tr1-like'). However, these markers do not distinguish between Tr1-like cells and other IL-10-producing cells in this model.

IL-10 production by Tr1-like cells is transient and wanes after the peak of inflammation {#s2-5}
----------------------------------------------------------------------------------------

We next sought to determine the kinetics of IL-10 production and airway inflammation in this model. To this end, we analyzed responses at day 2, day 6, day 16 and day 30 after allergic sensitization. For these experiments, the same protocol was used as in [Figure 1](#fig1){ref-type="fig"} but with additional analysis timepoints; a schematic of these is shown in [Figure 5A](#fig5){ref-type="fig"}.

![IL-10 production by Tr1-like cells is transient and wanes after peak of inflammation.\
(**A**) 10BiT reporter mice on a C57Bl/6 background were administered PBS as control or HDM and analysis was performed on groups of mice at the indicated times shown. (**B**) The total number of cells and (**C**) total number of eosinophils in the BAL were determined. n=3-5 animals per group per time point. Error bars represent standard deviation of the mean. (**D**) Representative flow cytometry plots showing the kinetics of IL-10-producing T cell subsets as identified by surface expression of CD90.1 and Foxp3+ regulatory T cell subsets as identified by GFP expression. The frequency of (**E**) IL-10-producing Foxp3- (CD90.1+Foxp3-), (**F**) IL-10-producing Foxp3+ (CD90.1+Foxp3+) within all CD4+ T cells is plotted at indicated analysis days. n=3-5 animals per group per time point. Error bars represent standard deviation of the mean. Statistical significance was determined using 2-way ANOVA (post hoc test: Sidaks). (**G**) Cells from lungs of HDM- treated mice obtained after Day 26 and day 30 were stimulated with PMA, Ionomycin and Brefeldin and surface stained, fixed and permeabilized for detection of cytokines. The frequency of CD90.1+Foxp3- T cells producing IL-10, IFNγ, IL-13 and IL-17 is shown for indicated time points. (**H**) To identify lung resident T cells, intravascular (IV) labeling of cells was performed by retroorbital injection of CD45 antibody and mice were euthanized 2 minutes after injection. The ratio of resident to circulating cells within indicated CD4+ T cells from lungs of HDM-treated mice obtained at day 30 post first challenge is plotted. (**I**) The frequency of effector (TEM) (CD62l-CD44+), central (TCM) (CD62l+CD44+), and naïve subsets(CD62L+CD44-) within CD90.1+Foxp3- cells in lungs at day 30 post first allergen challenge is plotted. Data representative of three independent experiments \*\*\*P$\leq$0.001, \*\*\*\*P$\leq$0.0001 GFP= green fluorescent protein. PMA= phorbol myristate acetate, IFNγ= Interferon gamma.\
10.7554/eLife.44821.017Figure 5---source data 1.IL-10 production by Tr1-like cells is transient and wanes after peak of inflammation.](elife-44821-fig5){#fig5}

The inflammatory response peaked on day 16 as measured by total cellular ([Figure 5B](#fig5){ref-type="fig"}) and eosinophilic infiltration ([Figure 5C](#fig5){ref-type="fig"}) in the BAL. By day 30, inflammation was largely resolved. The frequency of CD90.1+Foxp3- (Tr1-like cells) within the CD4+ T cell population was likewise maximal at day 16 and waned by day 30 ([Figure 5D,E](#fig5){ref-type="fig"}). The frequency of CD90.1+Foxp3+ Treg was also maximal at day 16 ([Figure 5F](#fig5){ref-type="fig"}), while the frequency of CD90.1- Foxp3+ cells was unchanged (data not shown). Similarly, the frequency of CD90.1+ Foxp3- T cells also diminished in the BAL from Day 16 to day 30, whereas the CD90.1+Foxp3+ and CD90.1-Foxp3+ cells were unchanged ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"})

To directly measure IL-10 production independently of CD90.1, we performed intracellular cytokine staining on these cells' ex vivo. At the peak of inflammation on day 16 the majority of CD90.1+ Foxp3- cells produced IL-10 and insignificant amounts of IFNg, IL-13, or IL-17 in the lungs ([Figure 5G](#fig5){ref-type="fig"}) and in the BAL ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). However, by day 30 IL-10 production by CD90.1 cells had waned ([Figure 5G](#fig5){ref-type="fig"}).

These CD90.1+IL-10- 'former Tr1' remained within the lung parenchyma as assessed by intravenous labeling ([Figure 5H](#fig5){ref-type="fig"}). Moreover, majority of these cells were CD62L negative and CD44 high hence exhibiting an effector memory phenotype ([Figure 5I](#fig5){ref-type="fig"}).

Together, these data indicate that Tr1-like cells and not Foxp3+ Treg comprise the majority of IL-10+ T cells in this model. Further, these data suggest that some CD90.1+cells may contribute to the allergen specific memory T-cell pool.

Active IL-10 production in Tr1 like cells is associated with *Irf1* and *Batf* expression {#s2-6}
-----------------------------------------------------------------------------------------

Given the low levels of IL-10 production in CD90.1+ cells 30 days after antigenic challenge ([Figure 5G](#fig5){ref-type="fig"}), we questioned whether CD90.1+ cells require persistent antigenic signals for active IL-10 production. To address this, we isolated CD90.1+ cells from spleens of 10BiT mice and cultured them with or without anti-CD3 and anti-CD28 as described previously ([@bib10]) Only cells which were activated continued to produce IL-10 after 5 days in cell culture ([Figure 6A,B](#fig6){ref-type="fig"}). Moreover, the viability of cultured cells was severely affected in the absence of TCR stimulation over time ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

![Active IL-10 production is associated with *Irf1* and *Batf* expression.\
CD90.1- and CD90.1+ CD4 T cells were isolated from 10BiT spleens and cultured (**A**) unstimulated in plain media or (**B**) with CD3/CD28 stimulation for 5 days to assess kinetics of Thy1.1 surface expression and intracellular IL-10 cytokine staining. (**C**) *Irf1* expression and (**D**) *Batf* expression in indicated subsets obtained from in vitro differentiated Tr1 cell cultures. Data was normalized to beta actin as reference gene and is expressed as fold change over 90.1-IL-10- cells using delta C~t~ method. Expression data are pooled from five independent experiments.\
10.7554/eLife.44821.021Figure 6---source data 1.Active IL-10 production is associated with *Irf1* and *Batf* expression.](elife-44821-fig6){#fig6}

We then asked whether expression of *Irf1* and *Batf*; transcription factors associated with Tr1 cells and IL-10 production ([@bib25]), distinguished CD90.1+IL-10+ Tr1-like cells from CD90.1+IL-10- 'former' Tr1-like cells in an activation dependent manner. Using antibodies against CD90.1 and IL-10 cytokine capture assays we sorted CD90.1+IL-10+, CD90.1+IL-10-, and CD90.1-IL-10- cell populations, using the latter for normalization.

We found that *Irf1* and *Batf* are upregulated only in cells actively producing IL-10 ([Figure 6C,D](#fig6){ref-type="fig"}). These transcription factors therefore characterize active IL-10 production by Tr1-like cells in this model.

Tr1-like cells are a part of allergen-specific memory in the lungs of previously sensitized animals {#s2-7}
---------------------------------------------------------------------------------------------------

We next investigated the role of previous allergen exposure in IL-10 production. For this we established a long-term model of HDM challenge ([Figure 7A](#fig7){ref-type="fig"}). In brief, we sensitized animals to HDM over 2 weeks as before. Following this, the animals were rested for close to 2 months. Then, on day 67 after the first challenge, both PBS and HDM-sensitized animals were challenged with one dose of HDM, and the airway inflammatory response was analyzed 24 hr later. Looking this early after allergen challenge allowed us to better assess the rapid CD4 T cell allergen specific memory responses.

![Tr1-like cells contribute to allergen-specific memory T-cells in the lung.\
(**A**) Mice were administered either PBS as control or crude HDM intranasally (i.n.) Six times over 2 weeks as shown. The mice were then left unchallenged until day 67 when both PBS (control) and HDM-sensitized animals were challenged with HDM. Analysis was done one day after the rechallenge at day 68. (**B**) The total number of cells in the BAL was determined. Data are pooled from two experiments. Each symbol represents a single animal. Error bars represent standard error of mean. n=7 for control group, n=13 for HDM group. Statistical significance was determined using an unpaired two tailed students t test. (**C**) The total number of eosinophils in the BAL is also plotted. Data are pooled from two experiments. Each symbol represents a single animal. Error bars represent standard error of mean. n=7 for control group, n=13 for HDM group. Statistical significance was determined using an unpaired two tailed students t test. \*\*P$\leq$0.01, \*\*\*P$\leq$0.001. (**D**) The level of IgE in BAL supernatant was determined by ELISA. n=8 for control group n=16 for HDM group. (**E**) Representative flow cytometry plot showing all IL-10-producing cells within CD4+ T cells in lungs of control or HDM-treated animals at day 68. (**F**) Composition of IL-10-producing cells is shown by plotting the frequency of indicated cell types within all IL-10-producing (CD90.1+) cells. Data are pooled from two experiments. Each column is an individual animal. (**G**) Gating scheme showing the HDM specific T cells stained using Derp1 tetramer and the different T cell subsets that constitute the tetramer + CD4+ T cells in the lungs of HDM-treated animals. The frequency of IL-10-producing Foxp3- (CD90.1+Foxp3-), IL-10-producing Foxp3+ (CD90.1+Foxp3+), Foxp3+ cells which do not produce IL-10 (CD90.1-Foxp3+) and CD90.1-Foxp3- within all CD4+ T cells is plotted. (**H**) The frequency of Tetramer + cells within CD90.1-Foxp3- and CD90.1+Foxp3- cells in the lungs of HDM-treated animals is plotted. Error bars represent standard deviation of the mean. n=7. (**I**) PMA, Ionomycin and Brefeldin stimulated CD4 T cells from lungs of HDM-treated mice were surface stained, fixed and permeabilized for detection of cytokines. The frequency of cells producing IL-4, IL-13, IL-10, IFNγ and IL-17 within CD90.1+ Foxp3- (Tr1-like) CD4+ T cells is shown. Data are pooled from two experiments. N is between 4-13 mice per cytokine (**J**). The frequency of cells expressing transcription factors Tbet and GATA3 the within CD90.1+ Foxp3- (Tr1-like) CD4+ T cells is shown. Error bars represent standard deviation of mean. n=13. Data representative of three independent experiments.\
10.7554/eLife.44821.027Figure 7---source data 1.Tr1-like cells contribute to allergen-specific memory T-cells in the lung.](elife-44821-fig7){#fig7}

Using this protocol, we found that animals that received primary sensitization with HDM exhibited heightened airway inflammation ([Figure 7B](#fig7){ref-type="fig"}), increased eosinophils ([Figure 7C](#fig7){ref-type="fig"}), and heightened IgE upon rechallenge ([Figure 7D](#fig7){ref-type="fig"}). CD90.1+Foxp3- cells were increased in HDM-sensitized animals ([Figure 7E](#fig7){ref-type="fig"}) while the frequency of CD90.1+Foxp3+ as well as CD90.1-Foxp3+ cells were unchanged. Consequently, the frequency of Foxp3-CD4+ T cells within all IL-10-producing cells was also elevated in HDM-sensitized animals in comparison to control, although non-T cells remained the main producers of IL-10 in both groups ([Figure 7F](#fig7){ref-type="fig"}). These changes were specific to the lung as we did not observe any changes in these subsets in the draining lymph node nor spleens (not shown).

To interrogate the antigen specificity of these cells, we used an I-A^b^ tetramer containing epitope 117--124 of the Derp1 protein from HDM ([@bib21]). Most tetramer + cells were either CD90.1+Foxp3- or CD90.1-Foxp3- while all Foxp3+ cells irrespective of CD90.1 expression were negative for tetramer staining ([Figure 7G](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). The population of tetramer-positive Tr1-like cells increased upon antigenic challenge while tetramer-staining Foxp3+ Treg populations did not. Within CD90.1+Foxp3-CD4+ T cells, a greater frequency of cells were tetramer+ ([Figure 7H](#fig7){ref-type="fig"}).

To further define the functional phenotype of these CD90.1+ Foxp3- T cells, we measured cytokine production after ex vivo stimulation. We found that the majority of CD90.1+Foxp3- cells produced IL-10 and fewer cells produced other cytokines such as IL-4, IL-13, IFNg and IL-17 ([Figure 7I](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Additionally, we found that these Tr1-like cells also expressed low levels of GATA3 and higher levels of Tbet ([Figure 7J](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

Together, these data indicate that Tr1-like cells arise from the allergen-specific memory response in this model. Further, the tetramer-positive cells that produced IL-10 in this model were Tr1-like cells and not Foxp3+ Treg.

IL-10-producing T cells in the lung can arise from tissue resident memory cells {#s2-8}
-------------------------------------------------------------------------------

We next asked whether the Tr1-like cells found upon memory challenge are resident to the lung or circulating. Using the same long-term model of HDM challenge used in [Figure 6A](#fig6){ref-type="fig"}, we observed that most CD90.1+ cells exhibited an effector memory phenotype (CD44hi, CD62Llow) as compared to the CD90.1-Foxp3- cells ([Figure 8A](#fig8){ref-type="fig"}). In addition, using intravascular labeling, we found that CD90.1+Foxp3- cells had a higher ratio of resident to circulating T cells ([Figure 8B](#fig8){ref-type="fig"}).

![IL-10-producing T cells in the lung can originate from tissue resident memory cells.\
(**A**) Gating scheme showing different memory cell subsets of Tr1-like (CD90.1+Foxp3-) or (CD90.1-Foxp3-) CD4+ T cells in the lungs of mice treated with HDM using the same protocol outlined in Figure 6A. The frequency of each memory subset within CD90.1+Foxp3- CD4+ T cells or CD90.1-Foxp3- T cells in the lungs of HDM-treated mice is plotted on the left. Data are pooled from two experiments. Error bars represent standard error of mean. n=10 for control group, n=10 for HDM group. To identify lung resident T cells, intravascular (IV) labeling of cells was performed by retroorbital injection of CD45 antibody and mice were euthanized 2 minutes after injection. (**B**) Representative flow cytometry plot showing resident versus circulating T cells within CD90.1+Foxp3- and CD90.1-Foxp3- CD4+ T cells from lungs of HDM-treated mice is shown. The ratio of resident to circulating cells within CD90.1+Foxp3- and CD90.1-Foxp3- CD4+ T cells from lungs of HDM-treated mice is plotted. Data are pooled from two experiments. Error bars represent standard error of mean. n=9 for control group, n=9 for HDM group. Statistical significance was determined using an unpaired two tailed students t test. Data representative of three independent experiments (**C**) To block lymphocyte egress from lymph nodes, HDM-sensitized animals were treated with FTY720. (**D**) The total number of cells in the BAL was determined. Each symbol represents a single animal (**E**) The total number of eosinophils in the BAL is also plotted. Each symbol represents a single animal. (**F**) The ratio of CD62L+/CD62L- CD4+ T cells in the lungs is plotted. (**G**) The frequency of CD90.1+Foxp3- CD4+ (Tr1-like T cells) and CD90.1-Foxp3- CD4+ (conventional T cells) in the lungs of control or FTY720-treated mice is shown. (**H**) Frequency of different memory subsets within CD90.1+Foxp3- (Tr1-like cells) and (**I**) CD90.1-Foxp3- (T conventional) cells in the lungs of control or FTY720-treated animals is plotted. n=5 for each group. \*\*P$\leq$0.01 TEM=Effector memory TCM =T central memory.\
10.7554/eLife.44821.033Figure 8---source data 1.IL-10-producing T cells in the lung can originate from tissue resident memory cells.](elife-44821-fig8){#fig8}

To functionally address tissue residency of these cells, we treated mice sensitized to HDM with the S1P receptor agonist FTY720 to block T cell egress from lymph nodes prior to memory rechallenge ([Figure 8C](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). We found that disruption of lymphocyte egress did not affect cellular infiltration or eosinophilia in the BAL ([Figure 8D,E](#fig8){ref-type="fig"}). However, the ratio of CD62L+ to CD62L- CD4+ T cells in the lungs was significantly reduced ([Figure 8F](#fig8){ref-type="fig"}). This is in line with a previous report that lung resident CD62L negative memory cells are sufficient to induce airway inflammation ([@bib21]). Notably, the frequency of Tr1-like cells within the CD4+T cells in the lungs was unaffected ([Figure 8G](#fig8){ref-type="fig"}). Unlike CD90.1-Foxp3- T cells, most of the CD90.1+Foxp3- Tr1-like cells were consistently effector memory (CD44hi CD62L low) both with and without FTY270 administration ([Figure 8H,I](#fig8){ref-type="fig"}).

To address the memory phenotype of our CD90.1+Foxp3- CD4 T cells in the lung parenchyma, we analyzed lungs from memory mice on day 68 without allergen rechallenge looking for common markers of tissue-residency ([@bib4]; [@bib41]). We find that when compared to unsensitized mice, CD90.1+Foxp3- cells in HDM-sensitized mice show higher frequencies of CD69 expression and lower frequencies of Ly6C expression. There was no difference in CCR7, CD103, IL7Ra or KI67 expression in CD90.1+Foxp3- cells between sensitization conditions. CD90.1-Foxp3- cells showed no difference in expression of any of the markers analyzed between sensitization conditions. ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}).

Together, these data indicate that the majority of CD90.1+Foxp3- CD4+ Tr1-like cells following allergen challenge have a memory phenotype and can arise from lung-resident memory cells.

Neither depletion nor adoptive transfer of Tr1-like cells influences tolerogenic responses to allergen re-challenge {#s2-9}
-------------------------------------------------------------------------------------------------------------------

To elucidate the functional contribution of Tr1-like cells to allergic inflammation, we next examined their function using depletion experiments. To this end we administered an antibody directed against CD90.1 to deplete IL-10 producing cells, as has been done previously to deplete CD90.1+ cells in this model ([@bib31]). The strategy was likewise successful here in depleting all CD90.1+ cells including CD90.1+Foxp3- and CD90.1+Foxp3+ T cells from the lungs ([Figure 9A,B](#fig9){ref-type="fig"}). Importantly the antibody clone used for depleting these cells did not mask CD90.1 staining with other clones ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). In addition, it depleted CD90.1+CD3- cells however, IL-10 production by them was unaffected ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}).

![Depletion of CD90.1+Foxp3- IL-10 competent Tr1 cells does not influence long-term tolerance to airway allergens.\
(**A**) Schematic illustrating the protocol used in experiments A-E. CD90.1+ cells were depleted in the sensitization phase using an anti CD90.1 antibody as depicted. Control animals were given matched isotype. (**B**) Representative flow cytometry plots showing the efficiency of depletion of CD90.1+ CD4 T cells in the lungs. Frequency of CD90.1+Foxp3- and CD90.1+Foxp3+ cells within CD4+ T cells in lungs of isotype or anti CD90.1 treated mice are plotted. Error bars represent standard deviation of the mean. n = 4 for isotype group, n = 5 for anti-CD90.1 group. Statistical significance was determined using 2-way ANOVA (post hoc test: Sidaks). (**C**) The total number of cells and (**D**) total number of eosinophils in the BAL was determined. Each symbol represents a single animal. Error bars represent standard deviation of mean. (**E**) Lung CD4 cells from isotype or anti-CD90.1 treated mice were restimulated with PMA, Ionomycin and Brefeldin A, surface stained, fixed and permeabilized for detection of intracellular cytokines. The frequency of cells producing IL-13, IL-17, and IFNγ within Foxp3- CD90.1- CD4+ T cells are shown. Error bars represent standard deviation of mean. n = 4 for isotype group, n = 5 for anti CD90.1 group. (**F**) Schematic illustrating the protocol used in experiments F-K. CD90.1+ cells were depleted using an anti CD90.1 antibody as depicted. Control animals were given matched isotype. (**G**) Representative flow cytometry plots showing the efficiency of depletion of CD90.1+ CD4 T cells in the lungs. Frequency of CD90.1+Foxp3- and CD90.1+Foxp3+ cells within CD4+ T cells in lungs of isotype or anti CD90.1 treated mice are plotted. Error bars represent standard deviation of the mean. n = 7 for isotype group, n = 5 for anti CD90.1 group. Statistical significance was determined using 2-way ANOVA (post hoc test: Sidaks). (**H**) The total number of cells and (**I**) total number of eosinophils in the BAL was determined. Each symbol represents a single animal. Error bars represent standard deviation of mean. (**J**) Lung CD4 cells from isotype or anti-CD90.1 treated mice were restimulated with PMA, Ionomycin and Brefeldin A, surface stained, fixed and permeabilized for detection of cytokines. The frequency of cells producing IL-13, IL-17, and IFNγ within Foxp3- CD90.1- CD4+ T cells are shown. Error bars represent standard deviation of mean. n = 7 for isotype group, n = 5 for anti CD90.1 group. (**K**) The frequency of Tetramer + cells within CD90.1-Foxp3- and CD90.1+Foxp3- cells in the lungs of HDM-treated animals is plotted. Error bars represent standard deviation of the mean. n = 7 for isotype group, n = 5 for anti CD90.1 group. Data representative of at least two independent experiments.\
10.7554/eLife.44821.039Figure 9---source data 1.Depletion of CD90.1+Foxp3- IL-10 competent Tr1 cells does not influence long-term tolerance to airway allergens.](elife-44821-fig9){#fig9}

We first depleted the CD90.1+ cell population during the sensitization phase ([Figure 9A,B](#fig9){ref-type="fig"}). This exacerbated airway inflammation as measured by total cell and eosinophil infiltration in the BAL ([Figure 9C,D](#fig9){ref-type="fig"}) as well as IL-13 production by CD90.1-Foxp3- CD4+T cells ([Figure 9E](#fig9){ref-type="fig"}).

We next depleted the CD90.1+ cell population during the memory phase ([Figure 9F,G](#fig9){ref-type="fig"}). This did not impact the inflammatory response ([Figure 9H,I](#fig9){ref-type="fig"}), cytokine production by CD90.1-Foxp3- cells ([Figure 9J](#fig9){ref-type="fig"}), nor the frequency of tetramer + cells within CD4+T cells in the lungs ([Figure 9K](#fig9){ref-type="fig"}).

We also performed intra-tracheal adoptive transfer of memory CD90.1+ Tr1-like cells or CD90.1- T effector cells from lungs of memory rechallenged mice sensitized to HDM or an unrelated allergen (ovalbumin) into naïve recipients who were subsequently challenged with HDM. Consistent with our observations in the depletion studies, we did not see any beneficial impact of the transfer of memory Tr1-like cells on cellular infiltration or eosinophilia in the BAL ([Figure 10A--C](#fig10){ref-type="fig"}). Moreover, the transferred CD90.1+ T cells were not more likely than transferred CD90.1- T cells to produce IL-10 upon rechallenge with allergen ([Figure 10D](#fig10){ref-type="fig"}) and did not alter the levels of IL-10 in the lung ([Figure 10E](#fig10){ref-type="fig"}). In contrast, CD90.1+Foxp3- cells could suppress cell infiltration in the BAL when transferred in an acute model and were also suppressive in vitro ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). This suggests that CD90.1+Foxp3- cells are unable to suppress the allergen specific inflammatory memory responses. An inherent problem of this model is that neither CD90.1+ nor CD90.1 negative cells engraft efficiently in the lungs ([Figure 10---figure supplement 2](#fig10s2){ref-type="fig"}).

![Transferred CD90.1+Foxp3- IL-10 competent Tr1 cells are not more likely than other T-cells to make IL-10 upon memory challenge to allergen.\
(**A**) All T cells or Tr1-like like cells or Effector T cells were isolated from lungs of HDM-sensitized animals after challenge and transferred into recipient groups as described. (**B**) Total cellular infiltration in the BAL and (**C**) eosinophilia in the BAL in recipients after HDM challenge is plotted. (**D**) Frequency of IL-10 expressing cells in lungs of recipient mice after 4 hr restimulation ex vivo with PMA/ionomycin/Brefeldin. (**E**) IL-10 ELISA from BAL fluid of recipient lungs. Error bars represent standard deviation of mean. n = 5 for group A, n = 4 For group B and n = 3 for group C.\
10.7554/eLife.44821.045Figure 10---source data 1.Transferred CD90.1+Foxp3- IL-10 competent Tr1 cells are not more likely than other T-cells to make IL-10 upon memory challenge to allergen.](elife-44821-fig10){#fig10}

Together these data indicate that during primary allergen challenge CD90.1+ cells, the majority of which are Tr1-like cells but also include some CD90.1+Foxp3+, promote immune tolerance. However, endogenous Tr1-like cells do not contribute to tolerogenic memory in this model.

Discussion {#s3}
==========

We have investigated the phenotypic stability and contributions to tolerogenic memory of endogenous Tr1-like cells in a mouse model of allergic airway inflammation-induced asthma. We report that natural Tr1-like cells only transiently express IL-10 after activation. Moreover, while cells that actively produce IL-10 are important for immune tolerance to airway allergens, neither depletion nor transfer of Tr1-like cells altered airway inflammation upon subsequent allergen challenge. Together these data suggest that naturally-arising Tr1-like cells may promote tolerance but do not contribute to a functionally stable tolerogenic memory population in this model.

Persistent antigenic signals were required for maintenance of IL-10 production and expression of *Irf1* and *Batf,* transcription factors previously linked to Tr1 status. It may be that repeated stimulation, a feature of many immunotherapy regimens, maintains active IL-10 production in airway Tr1-like cells by supporting expression of these canonical Tr1 transcription factors. In the gut, a prominent site of IL-10 production, antigen stimulation by commensal bacteria may provide a similar function ([@bib13]; [@bib14]; [@bib52]).

In light of these data, we propose that IL-10 production is a temporary phenotype that a fraction of memory T cells adopt upon activation in the setting of certain previously defined differentiation signals ([@bib49]; [@bib22]; [@bib17]; [@bib29]; [@bib11]; [@bib8]). Furthermore, IL-10 production in response to allergen exposure may be stochastic and not necessarily predicated upon past production of IL-10. This model is perhaps consistent with past reports of phenotypic plasticity in induced Foxp3+ regulatory T cells ([@bib24]; [@bib23]), and between T-helper subsets in general ([@bib53]). Notably, the data presented here involving naturally arising Tr1-like cells stands in contrast to more phenotypically stable Tr1-like cells that have been engineered or differentiated in vitro ([@bib18]).

Natural Tr1-like cells arise from the memory T-cell subset of mice previously sensitized to HDM. During the acute response, there is a significant increase in the frequency of CD90.1+Foxp3-, Tr1-like cells in the lungs and airways, the site of allergen challenge. After cessation of IL-10 production, these cells persisted over time in the lungs of challenged animals as tissue-resident memory cells. This is consistent with evidence that an immune reaction to an antigen can contribute to subsequent regulatory memory responses ([@bib6]; [@bib36]; [@bib39]; [@bib40]; [@bib16]).

Tr1-like cells in this model arose specifically in the lung, the site of allergen challenge and not in distal compartments such as the spleen. This is analogous to the report from Hondowicz et al. that tissue-resident Th2 cells drive allergic responses ([@bib21]). These data are also consistent with previous reports of tissue-specific roles for Tr1-like cells (though there are indications of geographic plasticity as well; [@bib52]). However, currently the most commonly used routes for allergen-specific immunotherapy (SIT) are subcutaneous and oral. The data presented here suggest that intranasal routes may be more effective at inducing Tr1-like cells in the lung ([@bib44]).

Tr1-like cells and not Foxp3+ Treg were the major source of IL-10 in the lung in this model. Consistent with this, there was a greater increase in the frequency of Tr1-like cells versus Foxp3+ Tregs in the lung during the peak of inflammation. Unlike Tr1 cells, the majority of CD90.1-Foxp3+ Tregs in the inflamed lung were circulating, non-resident cells and their frequency did not increase upon memory allergen rechallenge.

Finally, Tr1-like cells and not Treg (irrespective of CD90.1+ expression) were also the predominant Derp1:I-A^b^ tetramer-positive IL-10+ cell population in the lungs after secondary rechallenge. One could speculate that Foxp3+ regulatory memory Tregs may regulate inflammatory responses directed against self- rather than non-self-antigens, such as the HDM allergen ([@bib37]; [@bib36]). However, they may be specific for other HDM epitopes not assessed in our study. CD90.1+Foxp3+ cells are fewer in number and their frequency doesn't change significantly upon allergen sensitization. However, like the Tr1-like cells, they are also parenchymal and highly activated expressing CD44, Lag3, PD-1 and KLRG1.Furthermore they are also depleted when we use the CD90.1 antibody. Thus, while Tr1-like cells are the primary source of IL-10 in our model, we cannot rule out their secondary contribution to supressing inflammation in our acute model.

Tr1-like cells in our model expressed most of the cell surface markers previously associated with Tr1 cells including CD44, Lag3, PD-1, and KLRG1. However, these markers did not distinguish between Tr1-like cells and CD90.1+Foxp3+ Treg. Other studies have likewise reported that while these Tr1 markers identify a highly suppressive subset, they are not consistently expressed by all IL-10-producing Tr1-like cells ([@bib13]; [@bib9]; [@bib46]). This variation in their phenotypic markers is also consistent with the model that in vivo, natural Tr1-like cells may not be functionally stable in the absence of a persistent antigenic stimulus.

These findings may inform efforts to develop Tr1-based tolerogenic therapies. The phenotypic instability reported here may limit efforts to re-establish tolerance by promoting Tr1-based tolerogenic memory in the absence of repeated antigen stimulation. It may prove advantageous to engineer Tr1-like cells in vitro for adoptive transfer ([@bib18]). Insight into the tissue-specific factors required for maintenance of Tr1 function in vivo will help better target both endogenous and engineered Tr1-like cells to induce long-term tolerance in patients.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type                      Designation                                                                                                          Source of reference                                              Identifiers                                                       Additional\
                                                                                                                                                                                                                                                                                            Information
  --------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------------
  Genetic Reagent (*M. musculus*)   *10BiT mice (Tg(Il10-Thy1)1Weav)*                                                                                    PMID: [17694059](https://www.ncbi.nlm.nih.gov/pubmed/17694059)   RRID: [MGI:3767675](https://scicrunch.org/resolver/MGI:3767675)   

  Genetic Reagent (*M. musculus*)   *Foxp3eGFP (Foxp3tm2Tch)*                                                                                            PMID: [15780990](https://www.ncbi.nlm.nih.gov/pubmed/15780990)   RRID: [MGI:3699400](https://scicrunch.org/resolver/MGI:3699400)   

  Genetic Reagent (*M. musculus*)   *B6.129(Cg)-Cd44^tm1Hbg^/J*                                                                                          PMID: [10528194](https://www.ncbi.nlm.nih.gov/pubmed/10528194)   RRID: [MGI:4942279](https://scicrunch.org/resolver/MGI:4942279)   

  Biological sample                 Crushed House dust mite (Der p 1: 1911.78 mcg/vial, Endotoxin: 15900 UE/vial)obtained from *D. pteronyssinus*        Greer Laboratories Inc, Lenoir, NC                               Cat: XPB70D3A25 Lot: 322781                                       20 ug house dust mite given intranasally

  Biological sample                 Crushed House dust mite (Der p 1: 2009.03 mcg/vial, Endotoxin: 9150 EU/vial) obtained from from *D. pteronyssinus*   Greer Laboratories Inc, Lenoir, NC                               Cat: XPB70D3A25 Lot: 279019                                       20 ug house dust mite given intranasally

  Antibody                          Rat monoclonal CD4 (clone RM4-4),                                                                                    Biolegend                                                        Cat: 100552                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal CD3 (clone 17A2),                                                                                     Biolegend                                                        Cat: 100220                                                       1:100 for flow cytometry

  Antibody                          Mouse monoclonal CD90.1 (Thy1.1)(clone OX-7)                                                                         Biolegend                                                        Cat: 202516                                                       1:150 for flow cytometry

  Antibody                          Rat monoclonal CD44 (clone IM7)                                                                                      Biolegend                                                        Cat: 103020                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal Lag3 (clone C9B7W)                                                                                    BD Biosciences                                                   Cat: 562346                                                       1:50 for flow cytometry

  Antibody                          Rat monoclonal CD49b (clone DX5)                                                                                     eBiosciences                                                     Cat: 12-5971-82                                                   1:50 for flow cytometry

  Antibody                          Rat monoclonal CD25 (clone PC61)                                                                                     Biolegend                                                        Cat: 102026                                                       1:100 for flow cytometry

  Antibody                          Syrian Hamster monoclonal KLRG1 (clone 2F1)                                                                          Biolegend                                                        Cat: 138411                                                       1:50 for flow cytometry

  Antibody                          Rat monoclonal PD1 (clone RMP1-30)                                                                                   Biolegend                                                        Cat: 109110                                                       1:50 for flow cytometry

  Antibody                          Rat monoclonal IL-10 (clone JES5-16E3),                                                                              Biolegend                                                        Cat: 505009                                                       1:20 for flow cytometry

  Antibody                          Rat monoclonal IFNg (clone XMG1.2),                                                                                  Biolegend                                                        Cat: 505839                                                       1:20 for flow cytometry

  Antibody                          Rat monoclonal IL-17 (clone TC11-18H10.1),                                                                           Biolegend                                                        Cat: 506917                                                       1:20 for flow cytometry

  Antibody                          Rat monoclonal\                                                                                                      eBiosciences                                                     Cat: 12-7133-41                                                   1:20 for flow cytometry
                                    IL-13 (clone eBio13A),                                                                                                                                                                                                                                  

  Antibody                          Rat monoclonal IL-4 (clone 11B11)                                                                                    Biolegend                                                        Cat: 504125                                                       1:20 for flow cytometry

  Antibody                          Mouse monoclonal T-bet (clone 4B10)                                                                                  Biolegend                                                        Cat: 644813                                                       1:20 for flow cytometry

  Antibody                          Rat monoclonal Gata-3 (clone TWAJ)                                                                                   eBiosciences                                                     Cat: 12-9966-42                                                   1:20 for flow cytometry

  Antibody                          Mouse monoclonal CD90.1 (Thy1.1) (clone OX-7)                                                                        Biolegend                                                        Cat: 202529                                                       1:150 for flow cytometry

  Antibody                          Rat monoclonal CD11b (clone M1/70)                                                                                   BD Biosciences                                                   Cat: 562128                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal MHC Class II (I-A/I-E) (clone M5/114.15.2)                                                            eBiosciences                                                     Cat: 86-5321-41                                                   1:100 for flow cytometry

  Antibody                          Rat monoclonal Ly-6C (clone HK1.4)                                                                                   Biolegend                                                        Cat: 128041                                                       1:200 for flow cytometry

  Antibody                          Mouse monoclonal CD64 (clone X54-5/7.1)                                                                              Biolegend                                                        Cat: 139307                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal Siglec F (clone S17007L)                                                                              Biolegend                                                        Cat: 155505                                                       1:200 for flow cytometry

  Antibody                          Rat monoclonal Ly-6G (clone 1A8)                                                                                     Biolegend                                                        Cat: 127617                                                       1:200 for flow cytometry

  Antibody                          Armenian Hamster monoclonal CD11c (clone N418)                                                                       Biolegend                                                        Cat: 117310                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal CD24 (clone M1/69)                                                                                    Biolegend                                                        Cat: 101839                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal CCR7 (clone 4B12)                                                                                     eBiosciences                                                     Cat: 48-1971-82                                                   1:100 for flow cytometry

  Antibody                          Rat monoclonal CD62L (clone MEL-14)                                                                                  Biolegend                                                        Cat: 104438                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal CD44 (clone IM7)                                                                                      Biolegend                                                        Cat: 103032                                                       1:100 for flow cytometry

  Antibody                          Rat monoclonal IL-7Ra (clone SB/199)                                                                                 Biolegend                                                        Cat: 121111                                                       1:100 for flow cytometry

  Antibody                          Mouse monoclonal Thy1.1/CD90.1 (clone HIS51)                                                                         eBiosciences                                                     Cat: 15-0900-82                                                   1:150 for flow cytometry

  Antibody                          Armenian hamster monoclonal CD69 (clone H1.2F3)                                                                      Biolegend                                                        Cat: 104511                                                       1:100 for flow cytometry

  Antibody                          Mouse monoclonal KI-67 (clone B56)                                                                                   BD Biosciences                                                   Cat: 558615                                                       1:100 for flow cytometry

  Antibody                          Armenian hamster monoclonal CD103 (clone 2E7)                                                                        Biolegend                                                        Cat: 121431                                                       1:100 for flow cytometry

  Other                             Derp1:I-Ab tetramer conjugated to PE                                                                                 Gift from James moon                                                                                                               20 nM for flow

  Antibody                          Rat monoclonal CD45 AF700 clone 30-F11 (Biolegend, San Diego, CA)                                                    Biolegend                                                        Cat: 103128                                                       3 ug/mouse

  Antibody                          InVivoMAb mouse monoclonal anti-mouse Thy1.1/CD90.1 (clone 19E12)                                                    BioXcell                                                         Cat: BE0214                                                       200 ug/mouse

  Chemical compound (drug)          Fingolimod (FTY720)                                                                                                  Sigma-Aldrich                                                    Cat: SML0700-5MG                                                  used at at 5 mg/kg, estimating 25 g per mouse
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All animals used, including 10BiT/Foxp3eGFP, were on a C57BL/6 background. 10BiT/Foxp3eGFP mice were generated by crossing 10BiT mice (*Tg(Il10-Thy1)1Weav)* ([@bib31]) with Foxp3eGFP (*Foxp3^tm2Tch^)* ([@bib19]) to homozygosity. The 10Bit strain contains a transgenic insertion consisting of the coding sequence of *Thy1^a^ (Thy1.1, CD90.1*) followed by SV40 poly A sequence, inserted into a mouse Il10 gene contained in a BAC. The FOXP3EGFP strain co-express EGFP and the regulatory T cell-specific transcription factor *Foxp3* under the control of the endogenous promoter. CD44 knockout (*Cd44^tm1Hbg^*/J) animals were purchased from Jackson Laboratory. All mice were bred and maintained in house in a conventional facility according to institutional guidelines. All animal experiments and use procedures were approved by the Institutional Animal Care and Use Committee at Stanford University School of Medicine.

Allergic airway inflammation model {#s4-2}
----------------------------------

Mice used for allergic airway sensitization ranged from 8 to 16 weeks of age. Mice were anesthetized with isoflurane (Henry-Schein, Dublin, OH) and challenged intranasally with 20 μg of house dust mite (HDM) extract (Greer Laboratories Inc, Lenoir, NC) in 50 μL sterile phosphate-buffered saline (PBS) on experimental days 1, 3, and five for sensitization and days 8, 10, and 12 for challenge. Endotoxin content of different lots varied but Derp1 content was the same. Only data from experiments using the same HDM lot were pooled. Single cell isolates from both the bronchoalveolar lavage (BAL) fluid and tissues were collected for staining and flow cytometry analysis of immune cell populations. For memory experiments, BAL fluid and tissues were collected 24 hr after animals were given an allergen rechallenge on day 67.

Isolation of cells from tissues {#s4-3}
-------------------------------

Tissues were processed as described previously ([@bib15]). Briefly, bronchoalveolar lavages (BAL) were performed with 1 mL flushes of the lung with sterile PBS containing 0.2% BSA. BAL fluid was treated with ACK RBC lysis buffer (5 min, 37 degrees C) before cell counting and flow cytometry.

Following removal of BAL fluid, lungs were perfused with 5 mL sterile PBS injected into the right ventricle. Lungs were removed, placed in RPMI media and cut with scissors to approximately 1 mm pieces before the addition of collagenase IV (Sigma-Aldrich, St. Louis, MO) to 150 U/mL and DNase I (Sigma-Aldrich, St. Louis, MO) to 25 U/mL for digestion. Lung tissue was digested for 37 degrees C for 45 min on a shaker. A single cell suspension was obtained by pressing digested tissue through a 70 μm cell strainer using the plunger of a 3 mL syringe followed by a wash with PBS containing serum and EDTA. Where applicable, spleen and lymph nodes were isolated and separated into a single cell suspension using a 70 μm cell strainer similarly. All tissues were treated with ACK RBC lysis following single cell suspension (5 min, 37 degrees C) for cell counting and flow cytometry.

Histology {#s4-4}
---------

Histology was performed as described previously ([@bib50]). Lungs were inflated with 700--800 µl of 10% neutral buffered formalin, embedded into paraffin. 5 μM thick sections were stained with haematoxylin (Sigma-Aldrich, St. Louis, MO) and eosin (Merck Millipore, Burlington, MA). Stained slides were imaged by light microscopy.

Flow cytometry and antibodies {#s4-5}
-----------------------------

Cell subsets were distinguished by surface staining for CD4 (clone RM4-4), CD3 (clone 17A2), CD90.1 (Thy1.1) (clone OX-7) and Foxp3 eGFP. Surface expression of canonical Tr1 markers was assessed by surface staining for CD44 (clone IM7), Lag3 (clone C9B7W), CD49b (clone DX5), CD25 (clone PC61), KLRG1 (clone 2F1), and PD1 (clone RMP1-30). All antibodies were purchased from Biolegend (San Diego, CA).

To analyse cytokine production, cells from lung digests were stimulated with 20 ng/mL PMA (Sigma-Aldrich, St. Louis, MO), 1 μg/mL Ionomycin (Sigma-Aldrich, St. Louis, MO) and 3 μg/mL Brefeldin A (eBioscience-ThermoFisher, Waltham, MA) for 4 hr at 37 degrees C. Cells were surface stained and then were fixed with 2% PFA. Cells were then stained intracellularly with IL-10 (clone JES5-16E3), IFNg (clone XMG1.2), IL-17 (clone TC11-18H10.1), IL-13 (clone eBio13A), IL-4 (clone 11B11), T-bet (clone eBio4B10), and Gata-3 (clone TWAJ) in permeabilization buffer (eBioscience-ThermoFisher, Waltham, MA). Derp1:I-A^b^ tetramer conjugated to PE was a kind gift from James Moon ([@bib21]). Cells were stained with 20 nM tetramer for 1 hr at room temperature prior to surface staining. Stained cells were acquired on BD FACS LSRII instruments in the Stanford Shared FACS Facility and analyzed using FlowJo software (FlowJo, LLC, Ashland, OR).

Intravascular labeling of cells {#s4-6}
-------------------------------

For staining of non-tissue-resident circulating cells in the lung, CD45 AF700 clone 30-F11 (Biolegend, San Diego, CA) was injected retro-orbitally 2 min before mice were euthanized ([@bib2]).

Blocking lymphocyte migration using FTY720 {#s4-7}
------------------------------------------

To block lymphocyte egress from lymph nodes, HDM-sensitized animals were given daily IP injections of FTY720 (Sigma-Aldrich Cat: SML0700-5MG) at 5 mg/kg, estimating 25 g per mouse, or DMSO (sham control) in saline from day 64 to day 68 ([@bib7]).

Depletion of IL-10-producing cells {#s4-8}
----------------------------------

Depletion of IL-10-producing cells was performed by intraperitoneal injection of 200 ug of anti-Thy1.1 antibody or matched isotype control (BioXCell, West Lebanon, NH). This was done on day eight for the acute model (as depicted in the schematic in [Figure 8A](#fig8){ref-type="fig"}) and beginning on day 64 in the memory model (as depicted in the schematic in [Figure 8F](#fig8){ref-type="fig"}).

In vitro Tr1 cultures for cell sorting and cytokine capture assays and qPCR {#s4-9}
---------------------------------------------------------------------------

Cells were isolated from spleens and lymph nodes of two mice, as described previously ([@bib15]). Naïve CD4 T cells were isolated using the EasySep Mouse Naïve CD4+ T Cell Isolation Kit (STEMCELL, Cambridge, MA) following manufacturer's instructions. Tr1 cells were differentiated in vitro as described previously ([@bib10]). Briefly, naïve CD4 T cells were cultured in Tr1 clone medium with murine IL-27 (25 ng/mL) on plates coated with anti-CD3 (2 ug/mL) and anti-CD28 (2 ug/mL) for 3 days. Cells were then re-activated on fresh anti-CD3/anti-CD28-coated plates in media without IL-27 for 4.5 hr to promote IL-10 secretion. IL-10 secreting cells were labeled using the Mouse IL-10 Secretion Assay Detection Kit (Miltenyi, Auburn, CA) following manufacturer's instructions and surface stained for CD3, CD4, CD90.1, and viability for sorting.

Cells were sorted on the BD FACS Aria II instruments in the Stanford Shared FACS Facility and processed using the TaqMan Gene Expression Cells-to-Ct kit (ThermoFisher, Waltham, MA), following manufacturer's instructions, to generate cDNA for analysis. Gene expression was quantified using PrimeTime qPCR Probe Assays from IDT (Coralville, IA) for Irf1 (Mm.PT.58.33516776), Batf (Mm.PT.58.33231426), and beta-Actin (Mm.PT.39a.22214843.g) and SensiFAST Probe Hi-ROX Kit (Bioline, Memphis, TN) for 40 cycles. Gene expression was calculated as a delta Ct value with beta-Actin as a reference gene and displayed as fold-change in expression normalized to the CD90.1-IL-10- sort group.

Adoptive transfer studies {#s4-10}
-------------------------

10BiT/Foxp3eGFP mice were sensitized with either HDM (n = 20) or ovalbumin (n = 5) following the standard memory protocol and rechallenged at day 67 post initial challenge with their respective antigen. Lungs were digested and pooled, and CD4+ T cells were isolated using the EasySep Mouse CD4+ T cell isolation kit (STEMCELL, Cambridge, MA). CD4+ T cells from ovalbumin-sensitized mice served as an antigen-inexperienced control (Group A). CD4+ T cells from HDM-sensitized mice were then separated using the EasySep Mouse CD90.1 Positive Selection Kit into CD90.1-enriched (Tr1, Group B) and CD90.1-depleted (effector, Group C) donor populations. These cells were transferred into naïve C57Bl/6 mice intratracheally. Group A mice received 1.53E6 antigen-inexperience CD4 T cells per mouse, Group B mice received 1.36E4 Tr1 enriched CD4 T cells, and Group C mice received 2.51E5 Tr1-depleted CD4 T cells. All groups were challenged with HDM 48 hr after transfer and BAL and lungs were analyzed.

Statistics {#s4-11}
----------

All graph generation and statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc, La Jolla, CA). Statistical tests used are specified in each figure legend. p\<0.05 was considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Natural Tr1-like cells do not confer long-term tolerogenic memory\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Benoit Salomon (Reviewer \#1).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

*Reviewer \#1:*

In this manuscript, Yadava et al., studied the role of Tr1-like cells (defined by the Foxp3- CD90.1/IL-10+ phenotype using 10BiT BAC transgenic mice to identify cells that produced or had produced IL-10) in a mouse model of lung allergy to the house dust mite allergen. They found that, at the peak of the disease (day 16), Tr1-like cells are the main IL-10 producer cells (Figure 1F,G and Figure 2B). However, the other main findings (role of antigen persistence to maintain IL-10 expression by Tr1-like cells (Figure 4), role of Tr1-like cells assessed in depleting experiment (Figure 8), role of Tr1-like cells assessed in transfer experiment (Figure 9) are over-interpreted for the reasons explained below.

Essential revisions:

1\) The most critical experiments of this manuscript have been done only once with 3-5 mice per group (Figure 4, Figure 8 and Figure 9, and probably (not indicated) also Figure 2 and Figure 5) and all the other experiments have been only two times. Whereas two times is borderline but acceptable when results are striking, which is the case here for some experiments, performing an experiment only one time is unacceptable. That is why experiments showing the existence of \"former\" Tr1-like cells or showing that Tr1-like cells are critical at the peak of the disease but no more during memory are over-interpreted.

2\) Another major point challenges the conclusions of the existence of \"former\" Tr1-like cells (Figure 4). The \"former\" Tr1 like cells, which are CD90.1+ that no more produce IL-10, represent {plus minus}75% at day 16 (peak of the disease) and 5-10% at day 30. The authors concluded from this finding that Tr1-like cells lost their capacity to produce IL-10 because of lack of Ag-stimulation. Another interpretation of the data is preferential survival or proliferation of IL-10- CD90.1+ cells over IL-10+ CD90.1+ cells. in vitro experiment depicted in Figure 5 does not help to solve this issue because it is a totally different system and we only have proportions and not absolute numbers that may help to distinguish between these two mechanisms (IL-10 loss vs preferential survival or proliferation).

3\) Another major point challenges the conclusions that Tr1-like cells are dispensable to maintain immune tolerance, shown in the depleting experiment (Figure 8). Indeed, it is very likely that the \"former\" Tr1-like cells loose CD90.1 expression after silencing of the IL-10 promoter over time. Thus, depleting CD90.1+ cells would not deplete these \"former\" Tr1-like cells. To address this major concern, critical data are missing. What is the half-life of CD90.1 (both mRNA and protein) when the gene is no more transcripted. Also, we do not know how profound the depletion of CD90.1+ cells is, since the authors have not checked whether the depleting mAb could mask the CD90.1 staining.

4\) Another major point challenges the conclusions that Tr1-like cells are dispensable to maintain immune tolerance, shown in the transfer experiment (Figure 9). The positive control is missing here. The authors should show that transferring Tr1-like cells purified from day 16 (peak of the disease) are able to control the disease. Without this positive control, we do not know if the cell transfer experiment is working. Also, it would be better to have a normal model of lung allergy by injecting the allergen 6 times (and not 4 times that give a weak disease).

5\) The term \"resident\" for CD45- cells in the blood partitioning experiment is non-appropriate. The term \"parenchymal\" is more accurate since we do not if they are resident, before the experiment injecting FTY720. Also, we do not know how efficient, was the injection of FTY720. Critical control data, for instance looking at T cell numbers in the blood, are lacking. Data of Figure 7D to support FTY720 efficacy are too weak.

6\) The data on Irf1 and Batf are very weak. Only one experiment? No statistics.

*Reviewer \#2:*

IL-10-producing Tr1 cells have gained much interest because of their activity to suppress inflammatory responses, but it remains unclear whether they are functionally stable and capable of mediating tolerogenic memory. In the present study, Yadava et al. addressed this important question using a HDM model of allergic lung inflammation. They took advantage of IL-10-Thy1.1 BAC Tg x Foxp3-eGFP reporter mice to identify IL-10-expressing CD4^+^ T cell subsets in primary and secondary (recall) responses to HDM and to examine whether Tr1 cells play any role in the primary and secondary responses. The main results are; (1) during the primary response, Thy1.1+Foxp3-CD4^+^ T cells accumulate within the lung tissue but decrease in numbers and stop producing IL-10 after the peak of inflammation; (2) in the recall response, antigen-specific \"memory\" Thy1.1+Foxp3-CD4^+^ T cells can be detected within the lung tissues even in FTY720-treated mice; (3) while depletion of Thy1.1+ cells exacerbated inflammation in the primary response, their depletion failed to affect inflammation in the recall response; (4) adoptive transfer of \"memory\" Thy1.1+Foxp3-CD4^+^ T cells to naïve mice resulted in loss of Thy1.1 expression upon re-challenge and failed to affect inflammation. Based on these results, the authors conclude that Tr1 cells are not functionally stable and do not contribute to \"tolerogenic memory\" in this experimental setting.

In my view, there is one fundamental flaw that seriously questions the validity of the conclusions of this study. Thus, the authors\' definition of Tr1 cells as being Thy1.1+Foxp3-CD4^+^ T cells is inappropriate. Because IL-10 can be produced by different CD4^+^ T cell subsets, particularly Th2 cells, it is absolutely required to include other Tr1 cell markers including expression of CD49b and LAG3 as well and to exclude Th2 cells by using an IL-4 reporter to more rigorously define Tr1 cells. This is particularly important because the authors used a model of Th2 inflammation. It is also absolutely necessary to demonstrate that their \"Tr1\" or \"Tr1-like\" cells show suppressive activities. The exacerbated primary response to HDM after depletion of Thy1.1+ cells could be accounted for solely by depletion of Thy1.1+Foxp3+ Treg cells. No data demonstrate that Tr1 cells are actually generated in meaningful numbers in this experimental system. If so, the use of this experimental system is certainly inappropriate to address the main question of this study.

Essential revisions:

1\) Figure 6, Figure 7, Figure 8 and Figure 9: The authors should characterize the dynamics of CD4^+^ T cell subsets and of inflammatory responses during the recall response. It is surprising that the authors have analyzed mice only 1 day after the recall immunization. It is possible that depletion or transfer of Thy1.1+Foxp3-CD4^+^ T cells may affect inflammation when examined at later time points.

2\) Figure 6: A group of animals that have been primed by HDM but are not given HDM on day 67 is necessary. In the absence of this control, it is impossible to judge whether the observed responses in the experimental group reflect the recall response or the remnant of the primary response.

3\) Figure 7: Because FTY720 inhibits egress of lymphocytes from secondary lymphoid tissues to blood circulation, it is possible that Thy1.1+Foxp3- T cells do not originate from tissue resident memory cells but are recruited from effector memory cells that are circulating in the blood. To claim that they are derived from tissue-resident memory cells, parabiosis experiments are necessary.

4\) Figure 6G, Figure 7---figure supplement 1: To validate the specificity of Derp1 tetramer staining, staining with a control tetramer (i.e., a tetramer loaded with an irrelevant peptide) should also be performed.

5\) Figure 8: It is not clear whether depletion of Thy1.1+ cells was properly assessed. It seems that anti-Thy1.1 (clone OX7) was used for flow cytometric analyses of T cells from anti-Thy1.1 (or isotype control) mAb injected animals. Because the anti-Thy1.1 mAb used for depletion should compete with the anti-Thy1.1 mAb used for flow cytometric analyses, the apparent absence of \"Thy1.1+\" cells in the treated group may not be due to their depletion but could simply result from the competition of the two clones of antibodies. This possibility should be ruled out.

6\) Figure 8C,D: The magnitude of the response of the control (yet HDM-immunized) group is much less than that of the HDM-immunized group shown in Figure 1B, C but rather similar to the non-immunized group. There must be something wrong.

*Reviewer \#3:*

The authors demonstrate the phenotype of lung resident Tr1-like cells during mite sensitization. They clearly show the stability and the origin of lung Tr1 cells using an in vitro assay system. However, some issues need to be further addressed to confirm and strengthen their claims on the role of Tr1 cells in the lung.

Essential Revisions:

1\) The authors claim that the major source of lung IL-10 is Tr1-like cell after mite immunization because a half of IL10 positive cells is Foxp3-CD4^+^ (Figure 3B). However, total number of cells is also important to assess the contribution of IL-10 production. The total number of each cell population which produces IL-10 should be shown. The amount of IL-10 expression from each cell should also be addressed. In Figure 1, signal intensity of Thy1.1 (IL10) of Treg is higher than that of Tr1-like cells whereas the percentage is lower. As the original paper of the IL-10 reporter mice indicated that MFI of Thy1.1 can be used to estimate the IL-10 producing potential, they should summarize the MFI of Thy1.1 as the capacity of IL-10 expression, in addition to the percentage, of each cell population in order to support possible contribution of Tr1-like cells to the amount of lung IL-10.

2\) They appear to have carried out the in vivo labeling experiment without immunization in Figure 2 because IL-10+ cells are not so high (Figure 2C). As the origin of Tr1 cells during inflammation is more important, they have to address the issue under immunization.

3\) In Figure 5, they compare IL-10 production with or without in vitro TCR stimulation. Is it possible to maintain primary T cells in vitro without stimulation for 5 days? They should show the percentage of living cells after culture. If unstimulated cells are not normal, it\'s difficult to conclude that IL-10 production is dependent on TCR stimulation.

4\) In Figure 4G, they examine cytokine production from Thy1.1+ cells. Because IL-4 is a major Th2 cytokine, they should assess the production of IL-4.

5\) In Figure 7, they use FTY720 for inhibiting the egress of lymphocyte. As they only show the ratio of naïve/effector fraction in Figure 5F, it is difficult to understand the dynamics of CD4^+^ subsets. They should summarize the total number of each T cell subset with or without FTY720 treatment.

6 In Thy1.1 depletion experiments (Figure 8), not only Tr1 but also other IL-10 producing cell (e.g.; DCs, B cells and macrophages) population would be deleted. They should address the effects on other IL-10 producing cells, at least show the percentage and the number of other cell populations after anti-Thy1.1 treatment.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Natural Tr1-like cells do not confer long-term tolerogenic memory\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Tadatsugu Taniguchi (Senior Editor) and the Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have properly responded to the reviewers\' comments. One concern is their interpretation of the results in the depletion experiments in Figure 9 and Figure10, which are related to whether IL-10-producing T cells indeed bear in vivo suppressive activity in the allergy model. This issue was raised by one of the reviewers, but the authors\' response is not sufficiently convincing. In Figure 9A, B, there is still a possibility that depletion of Thy-1.1+Foxp3+ cells by anti-Thy-1.1 antibody is responsible for the exacerbation of the allergic response because these Foxp3+ cells are KLRG1+ (i.e., highly activated) even if the cell number is small as shown in Figure 4. Suppressive activity shown with in vitro induced Tr1 cells is not a proper support for their claim. However, the issue does not oppose their main claim that Tr-1-like cells do not possess suppressive activity on recall responses. Modification of their interpretation may be sufficient for final acceptance.

10.7554/eLife.44821.049

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> \[...\] Essential revisions:
>
> 1\) The most critical experiments of this manuscript have been done only once with 3-5 mice per group (Figure 4, Figure 8 and Figure 9, and probably (not indicated) also Figure 2 and Figure 5) and all the other experiments have been only two times. Whereas two times is borderline but acceptable when results are striking, which is the case here for some experiments, performing an experiment only one time is unacceptable. That is why experiments showing the existence of \"former\" Tr1-like cells or showing that Tr1-like cells are critical at the peak of the disease but no more during memory are over-interpreted.

Thank you for bringing this to our attention. However, this appears to be a misunderstanding. The experiments in question were instances where we did not list the number of experimental replicates. We have now included information on the number of experimental replicates throughout the manuscript.

> 2\) Another major point challenges the conclusions of the existence of \"former\" Tr1-like cells (Figure 4). The \"former\" Tr1 like cells, which are CD90.1+ that no more produce IL-10, represent {plus minus}75% at day 16 (peak of the disease) and 5-10% at day 30. The authors concluded from this finding that Tr1-like cells lost their capacity to produce IL-10 because of lack of Ag-stimulation. Another interpretation of the data is preferential survival or proliferation of IL-10- CD90.1+ cells over IL-10+ CD90.1+ cells. in vitro experiment depicted in Figure 5 does not help to solve this issue because it is a totally different system and we only have proportions and not absolute numbers that may help to distinguish between these two mechanisms (IL-10 loss vs preferential survival or proliferation).

Our conclusion that former Tr1 cells exist is based on data from 10Bit mice, a well characterized IL-10 reporter stain used in many studies in the past 12 years (Maynard and Weaver, 2008; Maseda et al., 2012; Moreira-Teixeira et al., 2017; Bouabe; Clement et al., 2016). In this reporter strain, CD90.1 is expressed only after IL-10 production. The presence of CD90.1 on Foxp3- Tcells in the absence of active IL-10 production can therefore only mean that these cells previously produced this cytokine but they do not currently -- that is to say that they are former Tr1.

Regarding the possibility that these former TR1 cells are over represented in our model due to ongoing proliferation, it is difficult to see how this could be the case in the absence of cognate antigen for a month and given the overall marked decline in the airway inflammatory cells during this time (Figure 5B). If the reviewer is instead suggesting that these CD90.1+ cells represent de novo proliferative responses of naïve cells to different (perhaps self?) antigens, this seems highly unlikely given that a large fraction of former Tr1 are memory T cells (Figure 5I). Nonetheless, to directly interrogate whether these former Tr1 show evidence of extensive proliferation, we examined Ki67 expression and found that the large majority (\>90%) were Ki67 negative (Figure 8---figure supplement 2). These data do not support extensive proliferation in former Tr1.

Regarding the possibility that Tr1 cells survive poorly in post-inflammatory tissues, we agree that this is possible. However, we do not see how it would challenge the conclusion that IL-10CD90.1+ T-cells are former Tr1. Moreover, this would fit well with our model because antigenic signals govern both T cell survival (Freitas and Rocha, 1999) as well as IL-10 production (Roncarolo et al., 2006). Nonetheless, to test this directly we examined the survival of purified IL10+CD90.1+ tr1 cells and find that ongoing antigenic signals are critical for Tr1 survival. These data are now included as Figure 6---figure supplement 1.

> 3\) Another major point challenges the conclusions that Tr1-like cells are dispensable to maintain immune tolerance, shown in the depleting experiment (Figure 8). Indeed, it is very likely that the \"former\" Tr1-like cells loose CD90.1 expression after silencing of the IL-10 promoter over time. Thus, depleting CD90.1+ cells would not deplete these \"former\" Tr1-like cells. To address this major concern, critical data are missing. What is the half-life of CD90.1 (both mRNA and protein) when the gene is no more transcripted.

The kinetics of CD90.1 expression and IL-10 in the 10Bit model were previously addressed in many studies (Maynard et al., 2007; Moreira-Teixeira et al., 2017; Maseda et al., 2012). In particular, it was reported that CD90.1 mRNA and IL-10 mRNA follow parallel dynamics after stimulation (Maseda et al., 2012) and that cell surface CD90.1 expression can persist for months (Maseda et al., 2012; Maynard et al., 2007). In our own experiments, we find that on Day 68 of our rechallenge protocol 3.7% of CD4^+^ T-cells in mice originally treated with HDM are CD90.1+ (Figure 7E). The CD90.1+Foxp3- subset memory cells at this time are predominantly memory cells (Figure 8---figure supplement 2). These are the cells that our depletion regimen could be expected to deplete.

> Also, we do not know how profound the depletion of CD90.1+ cells is, since the authors have not checked whether the depleting mAb could mask the CD90.1 staining.

To address this, we have used a distinct clone (Ox-7) to stain cells as compared to the antibody clone (19E12) which was used for depletion. We have included these data in figure 9---figure supplement 1, which shows that the depletion antibody does not mask the staining epitope of Ox7 clone as well as another fluorescently tagged CD90.1 clone (HIS51). To further support the efficient depletion of these cells in our system, we have also included data that show intracellular IL-10 protein is reduced in depleted groups (Figure 9---figure supplement 1)

> 4\) Another major point challenges the conclusions that Tr1-like cells are dispensable to maintain immune tolerance, shown in the transfer experiment (Figure 9). The positive control is missing here. The authors should show that transferring Tr1-like cells purified from day 16 (peak of the disease) are able to control the disease. Without this positive control, we do not know if the cell transfer experiment is working.

To address this and to provide a positive control for these experiments, we adoptively transferred 1 million in vitro induced Tr1 cells intratracheally into HDM sensitized recipients. We observed a decrease in total BAL counts and airway eosinophilia. We also showed that Tr1 cells are suppressive in vitro. (Figure 10---figure supplement 1).

> Also, it would be better to have a normal model of lung allergy by injecting the allergen 6 times (and not 4 times that give a weak disease).

This appears to be a misunderstanding. All of our experiments involved exposure to allergen 6 times. This point has been made clear in the methods section and in our graphics.

> 5\) The term \"resident\" for CD45- cells in the blood partitioning experiment is non-appropriate. The term \"parenchymal\" is more accurate since we do not if they are resident, before the experiment injecting FTY720.

Fingolimod (FTY720) has been widely used to investigate the role of tissue-resident cells in disease models (Hofmann et al., 2006; Janssen et al., 2015), including in the lungs (Connor et al., 2010). In the large majority of these studies, the term 'resident' is used for the cells spared by FTY720 treatment. We nonetheless appreciate the distinction between resident versus parenchymal cells is important and we now refer to these cells as parenchymal.

> Also, we do not know how efficient, was the injection of FTY720. Critical control data, for instance looking at T cell numbers in the blood, are lacking. Data of Figure 7D to support FTY720 efficacy are too weak.

To examine the effectiveness of FTY720 in depleting circulating cells in this model, we have included data on the absolute numbers of CD62L+ cells in mice treated with saline control vs. FTY720 as well as the absolute numbers of Tr1 and T conventional cells in different tissues (Figure 8---figure supplement 1). We find significantly fewer CD62L+ T cells in lungs of FTY720 mice compared to controls. In contrast there was no difference in the draining lymph nodes and spleen. We are confident that these data now strongly support the conclusion that FTY720 depletes circulating cells in this model as it has in other models (Hofmann et al., 2006; Connor et al., 2010; Janssen et al., 2015).

> 6\) The data on Irf1 and Batf are very weak. Only one experiment? No statistics.

Each data point in the bar graph in question actually represents a separate experiment (mean relative expression in triplicate) and the data are pooled from five independent experiments. We have now included information on the number of experiments and replicates in the figure legend as well as statistical analysis.

> Reviewer \#2:
>
> \[...\] In my view, there is one fundamental flaw that seriously questions the validity of the conclusions of this study. Thus, the authors\' definition of Tr1 cells as being Thy1.1+Foxp3-CD4^+^ T cells is inappropriate. Because IL-10 can be produced by different CD4^+^ T cell subsets, particularly Th2 cells, it is absolutely required to include other Tr1 cell markers including expression of CD49b and LAG3 as well and to exclude Th2 cells by using an IL-4 reporter to more rigorously define Tr1 cells. This is particularly important because the authors used a model of Th2 inflammation.

To determine whether the IL-10 producing cells in our model are Tr1 or Th2 we examined the expression of multiple Th2 markers including IL-4, IL-13, and GATA3. We find that none of these are present on our putative Tr1 cells (Figure 7---figure supplement 2). These data conclusively demonstrate that our Tr1-like cells are not Th2. Furthermore, we demonstrate that the Tr1 cells in this system are suppressive (Figure 10---figure supplement 1). As Th2 cells would not be expected to be suppressive, this further establishes that we are dealing with Tr1. Given the absence of any other Th2 markers, the suppressive capabilities of our Tr1, and the lack of any IL4 co-staining with our Tr1 in this system, we do not see the benefit of generating a triple reporter mouse with the capacity to track IL-4 as well as IL-10 and Foxp3.

Regarding the CD49b and LAG3 markers, in our model we find that CD49 is not associated with IL-10 expression while LAG3 is upregulated on all IL-10 producing cells including Foxp3+ Treg (Figure 4). We conclude that CD49 and LAG3 do not characterize IL-10+Foxp3- T-cells in this model and that the use of CD49b and LAG3 as Tr1 markers in this system is therefore not justified. We appreciate that this result contradicts data from some other models, notably the IL-10-GFP reporter strain. However, the reviewer may be aware that there is an active debate regarding the defining characteristics of Tr1 cells. In particular, CD49b and LAG3 have been identified as specific Tr1 markers in some studies and not in others (Huang et al., 2018; Burton et al., 2014). We hope the reviewer agrees that data should always be considered on its own merits and that input from different models and perspectives ultimately benefits the field.

> It is also absolutely necessary to demonstrate that their \"Tr1\" or \"Tr1-like\" cells show suppressive activities. The exacerbated primary response to HDM after depletion of Thy1.1+ cells could be accounted for solely by depletion of Thy1.1+Foxp3+ Treg cells. No data demonstrate that Tr1 cells are actually generated in meaningful numbers in this experimental system. If so, the use of this experimental system is certainly inappropriate to address the main question of this study.

To address this point and to provide a positive control for these experiments, we adoptively transferred 1 million in vitro induced Tr1 cells intratracheally into HDM sensitized recipients. We observed a decrease in total BAL counts and eosinophil counts. We also show that the Tr1 cells are also suppressive in vitro. These data are included in Figure 10---figure supplement 1.

> Essential revisions:
>
> 1\) Figure 6, Figure 7, Figure 8 and Figure 9: The authors should characterize the dynamics of CD4^+^ T cell subsets and of inflammatory responses during the recall response. It is surprising that the authors have analyzed mice only 1 day after the recall immunization. It is possible that depletion or transfer of Thy1.1+Foxp3-CD4^+^ T cells may affect inflammation when examined at later time points.

We examined recall responses after 1 day because this is the endpoint most relevant to clinical allergic asthma and to the studies of Tr1 cells planned or underway in human clinical studies. Furthermore, while fibrosis and airway remodeling can occur in chronic human asthma, the relevance of the available mouse models (or of Tr1 cells) to this pathophysiology is unclear (Moore and Hogaboam, 2008). Given these considerations, we did not feel that the proposed experiments were likely to make a productive contribution to the present work.

> 2\) Figure 6: A group of animals that have been primed by HDM but are not given HDM on day 67 is necessary. In the absence of this control, it is impossible to judge whether the observed responses in the experimental group reflect the recall response or the remnant of the primary response.

Given the normalization of BAL counts and Eosinophilia we observed by day 30 (Figure 4B) it was unclear to us why the reviewer believes that airway inflammation would not also have normalized on day 67.

Nonetheless, to address this, we sensitized mice with HDM or PBS control and waited until day 68 before analyzing BAL and lung tissues without rechallenge. We find no difference in total BAL counts (Figure 8---figure supplement 2). This demonstrates that the airway inflammatory response seen on day 68 following rechallenge is not a remnant of primary response but rather a rapid memory response to allergen re-exposure.

> 3\) Figure 7: Because FTY720 inhibits egress of lymphocytes from secondary lymphoid tissues to blood circulation, it is possible that Thy1.1+Foxp3- T cells do not originate from tissue resident memory cells but are recruited from effector memory cells that are circulating in the blood. To claim that they are derived from tissue-resident memory cells, parabiosis experiments are necessary.

While is true that FTY720 treatment prevents lymphocyte egress from secondary lymphoid organs, it is perhaps less well known that this drug actually targets multiple S1P s and has broader effects on leukocyte migration. In particular, it also targets endothelial cell barrier function and prevents entry of cells into lungs, CNS and other tissues (Hawksworth et al., 2012; Hutchison et al., 2009; Brinkmann et al., 2004). Moreover, it causes lymphopenia in the blood via a rapid reduction in circulating lymphocytes (Rosen et al., 2003; Tiper et al., 2016). We see similar reduction in our treatments as well.
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Given this circulating lymphopenia, it does not seem possible that circulating lymphocytes could populate the lungs and explain our findings. In addition CD90.1+Foxp3- cells in house dust mite sensitized animals show a CD69 hi, phenotype consistent with what is described for tissue resident memory cells (Figure 8---figure supplement 2). For this reason, we did not believe that the proposed parabiosis experiments were necessary.

> 4\) Figure 6G, Figure 7---figure supplement 1: To validate the specificity of Derp1 tetramer staining, staining with a control tetramer (i.e., a tetramer loaded with an irrelevant peptide) should also be performed.

The specificity of the Derp1 tetramer has been extensively validated elsewhere (Hondowicz et al., 2015; Moon and Pepper, 2018). To corroborate this reagent ourselves we examined Derp1 tetramer staining in animals not previously exposed to house dust mite. These data support the specificity of this reagent (Figure 7---figure supplement 1).

> 5\) Figure 8: It is not clear whether depletion of Thy1.1+ cells was properly assessed. It seems that anti-Thy1.1 (clone OX7) was used for flow cytometric analyses of T cells from anti-Thy1.1 (or isotype control) mAb injected animals. Because the anti-Thy1.1 mAb used for depletion should compete with the anti-Thy1.1 mAb used for flow cytometric analyses, the apparent absence of \"Thy1.1+\" cells in the treated group may not be due to their depletion but could simply result from the competition of the two clones of antibodies. This possibility should be ruled out.

To address this, we have used a distinct clone (Ox-7) to stain cells as compared to the antibody clone (19E12) which was used for depletion. We have included these data in Figure 9---figure supplement 1, which shows that the depletion antibody does not mask the staining epitope of Ox7 clone as well as another fluorescently tagged CD90.1 clone (HIS51).

In previous studies, many investigators, have taken advantage of the 10Bit mouse to deplete IL10 producing cells and demonstrated the loss of IL-10 protein by intracellular staining (Xin et al., 2018; Maynard et al., 2007). To further support the efficiency of depletion in our system, we have also included data that show intracellular IL-10 protein is reduced in depleted groups (Figure 9---figure supplement 1)

> 6\) Figure 8C, D: The magnitude of the response of the control (yet HDM-immunized) group is much less than that of the HDM-immunized group shown in Figure 1B, C but rather similar to the non-immunized group. There must be something wrong.

Baseline responses to house dust mite (HDM) antigen can vary for several reasons. First, unlike peptide antigens or recombinant proteins HDM is purified from crushed insects. Different lots of commercial HDM can have different relative potency (RP). Lots were normalized based on Der p 1 protein, however endotoxin levels between lots varied. Second, the RP of a single lot can vary over its shelf life. For this reason, the baseline responses in different figures can vary. This point has been clarified in the text. Nonetheless, to address the variability between these experiments, we show data for two independent depletion experiments in [Author response image 2](#respfig2){ref-type="fig"}.
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> Reviewer \#3:
>
> The authors demonstrate the phenotype of lung resident Tr1-like cells during mite sensitization. They clearly show the stability and the origin of lung Tr1 cells using an in vitro assay system. However, some issues need to be further addressed to confirm and strengthen their claims on the role of Tr1 cells in the lung.
>
> Essential Revisions:
>
> 1\) The authors claim that the major source of lung IL-10 is Tr1-like cell after mite immunization because a half of IL10 positive cells is Foxp3-CD4^+^ (Figure 3B). However, total number of cells is also important to assess the contribution of IL-10 production. The total number of each cell population which produces IL-10 should be shown. The amount of IL-10 expression from each cell should also be addressed. In Figure 1, signal intensity of Thy1.1 (IL10) of Treg is higher than that of Tr1-like cells whereas the percentage is lower. As the original paper of the IL-10 reporter mice indicated that MFI of Thy1.1 can be used to estimate the IL-10 producing potential, they should summarize the MFI of Thy1.1 as the capacity of IL-10 expression, in addition to the percentage, of each cell population in order to support possible contribution of Tr1-like cells to the amount of lung IL-10.

To address this point, we have added assessments of absolute cell numbers and Thy1.1 MFI assessments to Figure 3.

> 2\) They appear to have carried out the in vivo labeling experiment without immunization in Figure 2 because IL-10+ cells are not so high (Figure 2C). As the origin of Tr1 cells during inflammation is more important, they have to address the issue under immunization.

The image in question was indeed for a mouse that received PBS (a control mouse) and was provided to illustrate our gating strategy. To prevent any confusion, we have replaced this image with one from an immunized mouse (Figure 2).

> 3\) In Figure 5, they compare IL-10 production with or without in vitro TCR stimulation. Is it possible to maintain primary T cells in vitro without stimulation for 5 days? They should show the percentage of living cells after culture. If unstimulated cells are not normal, it\'s difficult to conclude that IL-10 production is dependent on TCR stimulation.

The data in Figure 5 (in current manuscript it is Figure 6) are gated on live cells only. Nonetheless, the reviewer is correct that in the absence of TCR stimulation both the viable cell numbers as well as IL-10 levels are low. To accompany these data, we have added the viability data as Figure 6---figure supplement 1. We have also added statements to the text clarifying the inter-relatedness of these points. With regards to the second comment, the inability of CD90.1+ cells to produce IL-10 in vitro in the absence of antigenic stimulation has also been previously published in the original 10BiT paper (Maynard et al., 2007).

> 4\) In figure 4G, they examine cytokine production from Thy1.1+ cells. Because IL-4 is a major Th2 cytokine, they should assess the production of IL-4.

To address this, we have included a Figure 7---figure supplement 2 which shows that the CD90.1+ cells are negative for IL-4, IL-13 and Gata3 via intracellular staining. We also show that memory Tr1 cells do not produce IL-4 in Figure 7I and therefore do not become Th2-like over time.

> 5\) In Figure 7, they use FTY720 for inhibiting the egress of lymphocyte. As they only show the ratio of naïve/effector fraction in Figure 5F, it is difficult to understand the dynamics of CD4^+^ subsets. They should summarize the total number of each T cell subset with or without FTY720 treatment.

The total numbers of T cell subsets with or without FTY720 treatment has been added as Figure 8---figure supplement 1.

> 6\) In Thy1.1 depletion experiments (Figure 8), not only Tr1 but also other IL-10 producing cell (e.g.; DCs, B cells and macrophages) population would be deleted. They should address the effects on other IL-10 producing cells, at least show the percentage and the number of other cell populations after anti-Thy1.1 treatment.

This information has been added as a Figure 9---figure supplement 2. However, when detecting intracellular IL-10, it is the CD4 T cells which are the greatest IL-10 producers and are most affected by the treatment with the depletion antibody.

> \[Editors' note: the author responses to the re-review follow.\]
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> The authors have properly responded to the reviewers\' comments. One concern is their interpretation of the results in the depletion experiments in Figure 9 and Figure 10, which are related to whether IL-10-producing T cells indeed bear in vivo suppressive activity in the allergy model. This issue was raised by one of the reviewers, but the authors\' response is not sufficiently convincing. In Figure 9A, B, there is still a possibility that depletion of Thy-1.1+Foxp3+ cells by anti-Thy-1.1 antibody is responsible for the exacerbation of the allergic response because these Foxp3+ cells are KLRG1+ (i.e., highly activated) even if the cell number is small as shown in Figure 4. Suppressive activity shown with in vitro induced Tr1 cells is not a proper support for their claim. However, the issue does not oppose their main claim that Tr-1-like cells do not possess suppressive activity on recall responses. Modification of their interpretation may be sufficient for final acceptance.

We agree with the editors and reviewers that our study does not exclude a functional role for CD90.1+Foxp3+ cells in suppressing inflammation. We have now made changes to the text which draw attention to this caveat in our results and in the discussion. Our changes convey our data more accurately. We have also updated the main manuscript file with these changes. The focus and main conclusion of our study remains on Tr1-like cells.

[^1]: These authors contributed equally to this work.
